# Translational Research of Peritoneal Dialysis Solution with Dissolved Molecular Hydrogen.
> 腹膜透析液への分子状水素溶解に関するトランスレーショナルリサーチ


## Abstract

Maintaining peritoneal membrane integrity is a key challenge in long-term peritoneal dialysis (PD). This study evaluated hydrogen-enriched peritoneal dialysis solution (H2-PDS) in two settings. In a chronic kidney disease rat model, H2-PDS was administered intraperitoneally via subcutaneous port for 3 weeks. Histological analysis showed a significant rise in mesothelial cell count and a significant reduction in peritoneal thickness in the H2-PD group relative to controls. Immunostaining revealed elevated vimentin expression and apoptotic cells in the standard PD group, suggesting that H2 may mitigate PDS-associated peritoneal damage. A 2-week clinical feasibility trial enrolling 6 prevalent PD patients was completed without adverse events. In selected participants, effluent levels of CA125 and mesothelin increased, pointing to possible H2-mediated enhancement of mesothelial regeneration. These findings position H2-enriched PDS as a candidate next-generation dialysis solution warranting larger clinical investigation.

### Mechanism

H2 is proposed to suppress PDS-induced oxidative stress and apoptosis in mesothelial cells, thereby preserving peritoneal structural integrity and reducing fibrotic thickening.

## Bibliographic

- **Authors**: Nakayama M, Watanabe K, Hayashi Y, Terawaki H, Zhu WJ, Kabayama S, et al.
- **Journal**: Contrib Nephrol
- **Year**: 2018
- **PMID**: [30041222](https://pubmed.ncbi.nlm.nih.gov/30041222/)
- **DOI**: [10.1159/000485717](https://doi.org/10.1159/000485717)
- **Study type**: animal study
- **Delivery route**: injection / infusion
- **Effect reported**: positive

## Delivery context

Intravenous hydrogen-saline infusion is a clinic-only route and is not viable for everyday self-administration. For routine hydrogen intake, inhalation is the most practical route, but inhalation carries explosion risk and concentration matters (empirical LFL of 10%; high-concentration 66% / 100% devices are not recommended).

## Safety notes

Intravenous hydrogen-saline infusion is a clinic-only route and is not viable for everyday self-administration. For routine hydrogen intake, inhalation is the most practical route, but inhalation carries explosion risk and concentration matters (empirical LFL of 10%; high-concentration 66% / 100% devices are not recommended).

See also:
- [Inhalation concentration and LFL / UFL](https://h2-papers.org/en/safety-notes/inhalation-concentration)
- [Consumer Affairs Agency accident cases](https://h2-papers.org/en/safety-notes/accident-cases)
- [Inhalation safety threshold lineage](https://h2-papers.org/en/safety-notes/lineage)

---

> **Cite as**: H2 Papers — PMID 30041222. https://h2-papers.org/en/papers/30041222
> **Source**: PubMed PMID [30041222](https://pubmed.ncbi.nlm.nih.gov/30041222/)